Celgene's Multiple Myeloma Triplet Succeeds in Key Phase III Trial Post author:Sam Post published:February 5, 2018 Post category:BioPharma The international clinical study, OPTIMISMM, achieved its primary endpoint. Source: BioSpace You Might Also Like Confident Johnson & Johnson Flexes Its Muscles, Plans 10 Blockbuster Approvals by 2021 May 16, 2017 FDA Grants Merck's Keytruda Priority Review for Cervical Cancer March 12, 2018 Provectus Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In March 5, 2017
Provectus Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In March 5, 2017
